3/12
08:00 am
cldi
Calidi Biotherapeutics Presents its Innovative and Scalable Manufacturing Process for CLD-401 at the 9th Annual Bioprocessing Summit; FDA Feedback Support Company’s Approach to Manufacturing
Medium
Report
Calidi Biotherapeutics Presents its Innovative and Scalable Manufacturing Process for CLD-401 at the 9th Annual Bioprocessing Summit; FDA Feedback Support Company’s Approach to Manufacturing
3/9
09:31 pm
cldi
Calidi Biotherapeutics Announces Closing of $6.0 Million Underwritten Public Offering and Full Exercise of Underwriters' Over-Allotment Option [Yahoo! Finance]
Medium
Report
Calidi Biotherapeutics Announces Closing of $6.0 Million Underwritten Public Offering and Full Exercise of Underwriters' Over-Allotment Option [Yahoo! Finance]
3/9
08:50 pm
cldi
Calidi Biotherapeutics Announces Closing of $6.0 Million Underwritten Public Offering and Full Exercise of Underwriters’ Over-Allotment Option
Medium
Report
Calidi Biotherapeutics Announces Closing of $6.0 Million Underwritten Public Offering and Full Exercise of Underwriters’ Over-Allotment Option
3/6
08:51 am
cldi
Calidi Biotherapeutics Announces Pricing of $5.2 Million Underwritten Public Offering [Yahoo! Finance]
High
Report
Calidi Biotherapeutics Announces Pricing of $5.2 Million Underwritten Public Offering [Yahoo! Finance]
3/6
08:30 am
cldi
Calidi Biotherapeutics Announces Pricing of $5.2 Million Underwritten Public Offering
High
Report
Calidi Biotherapeutics Announces Pricing of $5.2 Million Underwritten Public Offering
3/5
05:57 pm
cldi
Calidi Biotherapeutics Announces Proposed Public Offering
High
Report
Calidi Biotherapeutics Announces Proposed Public Offering
2/20
08:00 am
cldi
Calidi Biotherapeutics Presents Data on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform at the 2026 AACR-IO Conference
Low
Report
Calidi Biotherapeutics Presents Data on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform at the 2026 AACR-IO Conference
2/12
08:00 am
cldi
Calidi Biotherapeutics To Present on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform in a Late-Breaking Abstract at the 2026 AACR-IO Conference
Medium
Report
Calidi Biotherapeutics To Present on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform in a Late-Breaking Abstract at the 2026 AACR-IO Conference
1/28
08:00 am
cldi
Calidi Biotherapeutics Provides Corporate Update and Key Value Drivers for 2026
Low
Report
Calidi Biotherapeutics Provides Corporate Update and Key Value Drivers for 2026